Explain The Performance And Treatment Of Osteoporosis

- Feb 28, 2019-

   Osteoporosis is a metabolic bone disease characterized by decreased bone mass and microstructural destruction of bone tissue, resulting in increased bone fragility and prone to fracture. In the rheumatology clinic, some patients who were treated for "compressed body pain after cooling" were found to be only osteoporosis after excluding other rheumatoid immune diseases. After treatment with anti-osteoporosis drugs, the symptoms gradually Improvement, so rheumatologists are very concerned about osteoporosis.

   Mild osteoporosis is generally asymptomatic and is only found on X-ray or physical bone density measurements. Heavier patients may have low back pain, fatigue or body bone pain. The bone pain is usually diffuse, there is no fixed part, and there is no tenderness or tenderness. The body pain is often aggravated after being cold. The patient mistakenly believes that it is “rheumat”. disease". Severe osteoporosis may be fractured due to mild activities such as coughing, sneezing, bending, weight-bearing or squeezing. Common spine compression fractures, fractures of the hips and ribs, sternum, etc., lead to shortened body, hunchback and thoracic Malformation, affecting vital capacity and respiratory function; and forced to stay in bed for a long time to increase bone loss after fracture, making the fracture extremely difficult to heal, the patient's quality of life and life expectancy decreased significantly.

   Osteoporosis is divided into three categories according to the cause: primary, secondary and idiopathic. Primary osteoporosis is divided into postmenopausal osteoporosis (type I) and senile osteoporosis (type II). Postmenopausal osteoporosis usually occurs in women 5 to 10 years after menopause, and is associated with estrogen deficiency; senile osteoporosis generally refers to osteoporosis occurring over the age of 70 years, and is associated with decreased calcitriol synthesis. Idiopathic osteoporosis mainly occurs in adolescents, and the cause is still unknown. Most of them have a genetic family history.

   The prevention and treatment of osteoporosis is mainly to improve the nutritional status, supplement calcium and vitamin D, so that the total daily intake of elemental calcium reaches 800 ~ 1200mg, in addition to increasing dietary calcium content, oral calcium carbonate, gluconic acid Preparations such as calcium and calcium citrate; supplementing active vitamin D to promote intestinal calcium absorption and increase renal tubular reabsorption of calcium, such as calcitriol or alfacalcidol. For drug interventions in high-risk populations, it is necessary to increase anti-bone resorption drugs such as bisphosphonates and calcitonins, especially for osteoporosis patients with pain symptoms.

   At the same time, minodronic acid is a novel heterocyclic bisphosphonate compound. The main intermediate is Ethyl trans-4-oxo-2-butenoate CAS 2960-66-9 for the treatment of osteoporosis and osteoporosis. The hyperemia caused by the disease and malignant tumors inhibits the bone resorption of osteoclasts and reduces bone turnover by inhibiting the activity of farnesyl pyrophosphate (FPP) synthase in osteoclasts, thereby preventing and treating osteoporosis.

  In addition to drug prevention and control, lifestyle changes are also very important. It is necessary to correct some bad habits and behavioral deviations, quit smoking, avoid alcohol, strengthen exercise, engage in outdoor activities, exercise with appropriate weight, enhance body balance and resilience, and reduce falls and accidents. The occurrence of fractures can stay away from osteoporosis, a "quiet killer" that threatens human health!